Unraveling the potential of neuroinflammation and autophagy in schizophrenia
European Journal of Pharmacology,
Год журнала:
2025,
Номер
997, С. 177469 - 177469
Опубликована: Март 5, 2025
Язык: Английский
Effect of metformin on olanzapine-induced weight gain: A 12-week randomised open-label study
Journal of Clinical Sciences,
Год журнала:
2025,
Номер
22(1), С. 11 - 17
Опубликована: Янв. 1, 2025
ABSTRACT
Background:
Olanzapine
is
an
atypical
antipsychotic
used
in
schizophrenia
and
bipolar
affective
disorder,
but
it
associated
with
weight
gain
metabolic
syndrome.
Metformin
known
to
decrease
insulin
resistance
abnormal
glucose
metabolism.
Therefore,
thought
that
metformin
might
prove
useful
preventing
induced
by
olanzapine.
Hence,
this
study
was
undertaken
assess
the
effect
of
on
body
weight,
mass
index
(BMI),
waist
hip
circumference,
waist-to-hip
ratio,
blood
levels
patients
receiving
olanzapine
observe
their
adverse
effects.
Methods:
Sixty-five
or
mania
were
randomly
assigned
for
12
weeks
treatment
10
mg/day
plus
850
(
n
=
33)
alone
32).
Body
BMI,
ratio
measured
at
baseline,
4,
8,
12.
Fasting
plasma
estimated
baseline
end
study.
Results:
59/65
(90.8%)
completed
The
increased
both
groups
relatively
less
along
In
who
received
metformin,
more
than
7%
observed
43.3%,
86.2%
those
only
olanzapine,
difference
parameter
statistically
significant
P
0.001).
had
decreased
significantly
week
Conclusion:
group
compared
Язык: Английский
The synthetic TRPML1 agonist ML-SA1 mitigates intracellular lipid accumulation induced by antipsychotics in vitro by stimulating release of extracellular microvesicles
Irene Chavarría-Cubel,
Yessenia L. Molina,
Bohdan Babiy
и другие.
Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids,
Год журнала:
2025,
Номер
unknown, С. 159611 - 159611
Опубликована: Апрель 1, 2025
Язык: Английский
Combined sulforaphane and β-sitosterol mitigate olanzapine-induced metabolic disorders in rats: Insights on FOXO, PI3K/AKT, JAK/STAT3, and MAPK signaling pathways
International Immunopharmacology,
Год журнала:
2024,
Номер
140, С. 112904 - 112904
Опубликована: Авг. 7, 2024
Язык: Английский
Second-Generation Antipsychotics Induce Metabolic Disruption in Adipose Tissue-Derived Mesenchymal Stem Cells Through an aPKC-Dependent Pathway
Cells,
Год журнала:
2024,
Номер
13(24), С. 2084 - 2084
Опубликована: Дек. 17, 2024
Metabolic
syndrome
(MetS)
is
a
cluster
of
metabolic
abnormalities,
including
visceral
obesity,
dyslipidemia,
and
insulin
resistance.
In
this
regard,
white
adipose
tissue
(vWAT)
plays
critical
role,
influencing
energy
metabolism,
immunomodulation,
oxidative
stress.
Adipose-derived
stem
cells
(ADSCs)
are
key
players
in
these
processes
within
vWAT.
While
second-generation
antipsychotics
(SGAs)
have
significantly
improved
treatments
for
mental
health
disorders,
their
chronic
use
associated
with
an
increased
risk
MetS.
study,
we
explored
the
impact
SGAs
on
ADSCs
to
better
understand
role
MetS
identify
potential
therapeutic
targets.
Our
findings
reveal
that
olanzapine
disrupts
lipid
droplet
formation
during
adipogenic
differentiation,
impairing
receptor
endocytosis,
turnover,
signaling.
also
alter
endolysosomal
compartment,
leading
acidic
vesicle
accumulation
lysosomal
biogenesis
through
TFEB
activation.
PKCζ
crucial
SGA-induced
nuclear
translocation
formation.
Notably,
inhibiting
restored
tyrosine
phosphorylation,
normalized
downstream
signaling
following
treatment.
This
activation
by
driven
phosphatidic
acid
synthesis
via
phospholipase
D
(PLD),
G
protein-coupled
(GPCR)
Overall,
clozapine
disrupt
homeostasis
PKCζ-dependent
manner.
These
highlight
as
valuable
tools
uncovering
cellular
dysfunction
vWAT
may
guide
development
new
strategies
mitigate
side
effects
drugs.
Язык: Английский